THRX
THESEUS PHARMACEUTICALS, INC. (THRX)
$12.132.8%▲
Market is closedMarket is closed – opens on 8 PM, 30 Jan 2023
– opens on 8 PM, 30 Jan 2023
Key Stats
$11.6001
Day's Range
$12.5422
$4.01
52-Week Range
$15.21
| Returns % | |
| 1 month return | 139.72% |
| 3 month return | 125.46% |
| 1 year return | 31.42% |
| 5 year return | 34.71% |
Analyst Recommendation
based on 11 analysts ratings
Buy
90%
Buy
9%
Hold
0%
Sell
Based on 11 Wall street analysts offering stock ratings for THESEUS PHARMACEUTICALS, INC.(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 79.97%Current
$12.13
Target
$21.83
Recommendation Trend
Based on 11 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 10 | 10 | 10 |
| Hold | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 456.8M |
| Book Value | $5.71 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -1.76 |
| Wall Street Target Price | 21.83 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 1.04 |
| Enterprise Value | 10.8M |
| Enterprise Value/Revenue | 0.0 |
| Enterprise Value/Ebitda | -0.23 |
Technicals
| 50 Day MA | 7.07 |
| 200 Day MA | 7.09 |
Institutional Holdings
Orbimed Advisors, LLC
44.02%
FMR Inc
12.41%
Foresite Capital Management V, LLC
8.62%
T. Rowe Price Associates, Inc.
3.57%
Foresite Capital Opportunity Management V, LLC
2.48%
Boxer Capital LLC
2.3%
Company Information
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
| Organization | THESEUS PHARMACEUTICALS, INC. |
| Employees | 26 |
| CEO | Dr. Iain D. Dukes D.Phil., DPHIL, M.A. |
| Industry | Services |
Discover more
Frequently Asked Questions
What is THESEUS PHARMACEUTICALS, INC. share price today?
Can Indians buy THESEUS PHARMACEUTICALS, INC. shares?
How can I buy THESEUS PHARMACEUTICALS, INC. shares from India?
Can Fractional shares of THESEUS PHARMACEUTICALS, INC. be purchased?
What are the documents required to start investing in THESEUS PHARMACEUTICALS, INC. stocks?
What are today’s High and Low prices of THESEUS PHARMACEUTICALS, INC.?
What are today’s traded volumes of THESEUS PHARMACEUTICALS, INC.?
What is today’s market capitalisation of THESEUS PHARMACEUTICALS, INC.?
What is the 52 Week High and Low Range of THESEUS PHARMACEUTICALS, INC.?
How much percentage THESEUS PHARMACEUTICALS, INC. is down from its 52 Week High?
How much percentage THESEUS PHARMACEUTICALS, INC. is up from its 52 Week low?
What are the historical returns of THESEUS PHARMACEUTICALS, INC.?
Who is the Chief Executive Officer (CEO) of THESEUS PHARMACEUTICALS, INC.?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*